Neutralization of IGFBP1 is able to decrease the higher lipolysis rate in eWAT of Wtap-HKO mice by inhibiting ADCY3/4/6/cAMP/PKA signaling pathway, which further ameliorates NASH progression in the Wtap-HKO mice. Here, IGFBP1 is linked to metabolic dysfunction-associated steatohepatitis.